Treatment strategies

Historically, antibiotics have been employed prophylactically and curatively to treat bacterial infections in aquaculture systems, in particular in the hatchery environment. Sulfamerazine has been used in US aquaculture since 1948 and antibiotics in general have undoubtedly been instrumental in the commercial success of many aquaculture hatcheries (Alderman and Michel, 1992). However, few antibiotics have been approved by authorities for use in seafood aquaculture and most are restricted to experimental use, or are used off-label (Lucchetti et al, 2004). Indeed, in the USA only four antibiotics have been approved for use in aquaculture - oxytetracycline, florfenicol, ormethoprim/sulfadimethoxine and sulfamerazine - whereas in Japan over 30 antibiotics have been approved for use in aquaculture (Reimschuessel and Miller, 2006). Although antibiotics are effective control measures, there are significant environmental consequences relating to 

Prophage integrated into genome and replicates with host cell 

Several studies have indicated AHL-mediated QS is implicated in disease of cultured aquatic invertebrates. Experimental exposure to mixed AHLs caused mortality in giant freshwater prawn (Macrobrachium rosenbergii) larvae, putatively due to the induction of virulence factors in associated microbial communities (Baruah et al, 2009). Further, elevated levels of 

In vivo studies of QS disrupting compounds have included the use of halogenated furanones in black tiger prawns (P. monodon) (Manefield et al, 2000), Artemia (Defoirdt et al, 2006) and rotifers (Tinh et al, 2007) and the use of cinnamaldehyde and cinnamaldehyde analogues in Artemia 

As our understanding of the microbial ecology and virulence mechanisms of important hatchery pathogens increases, a new world of specific biocontrol strategies will iso emerge. Rapid developments in comparative genomics, transcriptomics and proteomics (Wu et al, 2008) will enable 

---

Enzymes Degrading Macromolecules. Enzymes that degrade macromolecules such as membrane polysaccharides, stmctural and functional proteins, or nucleic acids, have all shown oncolytic activity. Treatment strategies include the treatment of inoperable tumors with pepsin (1) antitumor activity of carboxypeptidase (44) cytotoxicity of ribonudease (45—47) oncolytic activity of neuraminidase (48—52) therapy with neuraminidase of patients with acute myeloid leukemia (53) antitumor activity of proteases (54) and hyaluronidase treatment in the management of human soHd tumors (55). 

Detailed sampling can include, but is not limited to, the installation of monitoring well networks. After the wells have been installed, aquifer tests are typically performed. Once the aquifer tests are performed and the aquifer characteristics are determined, time series sampling for a given contaminant, or a surrogate, is undertaken. The combined results of these efforts provide the basis for development of a treatment strategy. Modeling can be used as part of this effort to help determine the best technical and most cost-effective techniques to be used at a site. 

Antitrypanosomal Drugs. Table 1 Different treatment strategies depending on the cause of hyperthyroidism... 

Dixon MJ (2006) Aromatase inhibitors in early beast cancer therapy a variety of treatment strategies. Expert Opin 7 (18)2465-2479... 

Clinical studies, available only for entacapone and tolcapone, support preclinical findings. A dose-dependent (100-800 mg) inhibition of the COMT activity of the erythrocytes can be seen after nitrocatechols. However, effective and sufficient dose levels of both entacapone and tolcapone, given concomitantly with L-dopa and DDC inhibitors to patients with Parkinson s disease, appear to be 100-200 mg. However, the treatment strategies of entacapone and tolcapone differ entacapone is a short-acting compound that is given with each dose of L-dopa, and COMT activity may even... 

These studies suggest that behavioral treatment strategies, such as CRA and CM, can be effective alone and as adjuncts to pharmacotherapy. Whether the emphasis is on abstinence, treatment retention, or medication compliance, the results of studies on behavioral approaches are promising. 

No treatment strategies were located for chronic low-level exposures to endosulfan. 

New, interactive in silico teaching and educational tools will be available for doctors and the greater public. This will help to improve professional skills and general health awareness. Future health-related implications of an individual s behavioural patterns or of various treatment strategies can be assessed and compared on the basis of long-term case predictions. 

Recent years have seen the emergence of successful treatment strategies for ischemic stroke, but these are most effective only when initiated within several hours after stroke onset. Therefore, extremely rapid diagnosis and initiation of treatment are critical in avoiding death or severe disability. 

Internal Carotid Artery Occlusion Acute stroke due to a distal ICA T (T = terminus) occlusion carry a much worse prognosis than MCA occlusions. In a recent analysis of 24 consecutive patients (median NIHSS 19) presenting with T occlusions of the ICA who were treated by lAT using urokinase at an average of 237 minutes from symptom onset, only four patients (16.6%) had a favorable outcome at 3 months. Partial recanalization of the intracranial ICA was achieved in 15 (63%), of the MCA in 4 (17%), and of the ACA in 8 patients (33%). Complete recanalization did not occur. The presence of good leptomeningeal collaterals and age <60 years were the only predictors of a favorable clinical outcome. New treatment strategies, such as the combination of IV rt-PA and lAT, or the use of new mechanical devices may improve the outcome in these patients. 

Nesbit GM, Luh G, Tien R, Barnwell SL. New and future endovascular treatment strategies for acute ischemic stroke. J Vase Interv Radiol 2004 15 S103-S110. 

FIGURE 4-4. General treatment strategies for angina follow in clockwise fashion from the top center. ACE-I, angiotensinconverting enzyme inhibitor ARB, angiotensin receptor blocker. 

A major component of any IHD treatment plan is control of modifiable risk factors, including dyslipidemia, hypertension, and diabetes. Treatment strategies for dyslipidemia and hypertension in the patient with IHD are summarized in the following paragraphs. Visit chapters in this textbook on the management of hypertension and dyslipidemia for further information. 

The development of CHD is a lifelong process. Except in rare cases of severely elevated serum cholesterol levels, years of poor dietary habits, sedentary lifestyle, and life-habit risk factors (e.g., smoking and obesity) contribute to the development of atherosclerosis.3 Unfortunately, many individuals at risk for CHD do not receive lipid-lowering therapy or are not optimally treated. This chapter will help identify individuals at risk, assess treatment goals based on the level of CHD risk, and implement optimal treatment strategies and monitoring plans. 

Radiologic and/or endoscopic procedures are usually required to objectively document the presence of ulcers. Barium studies have a high sensitivity and are considered first-line tests to radiographically document an ulcer. However, the cost and complexity of all of these tests has led to the promotion of an early empiric treatment strategy for patients at low risk for PUD-related sequelae (e.g., malignancy). An empiric treatment strategy is appropriate for patients less than 50 years of age who have mild or intermittent epigastric symptoms and no evidence of PUD-related systemic symptoms or complications. 

The principal goal of IBS treatment is to reduce or control symptoms. The treatment strategy is based on (1) the prevailing symptoms and their severity (2) the degree of functional... 

TABLE 26-4. Prevention or Treatment Strategies for Beta Interferon Adverse Effects38 39... 

Formulate an initial treatment strategy for a patient in generalized convulsive status epilepticus. 

Once the loading dose of the AED is administered, it is important to remember to initiate maintenance doses to ensure that therapeutic levels are sustained. Chronic and idiosyncratic side effects as well as potential drug interactions should be considered if the patient will continue AED therapy indefinitely. All drug therapy should be adjusted for any hepatic or renal disease states. Table 28-1 summarizes the drug doses used in SE, and Table 28-2 provides an example of an algorithm for the treatment of patients in SE. Published studies comparing these treatment strategies are summarized in Table 28-3. 

Describe nonpharmacologic treatment strategies that may be appropriate for AG. 

---